RVMDRevolution Medicines, Inc.Signing up patients
Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC
NSCLC · Non-small Cell Lung Cancer · Non-Small Cell Lung Cancer NSCLC · Non-Squamous Non Small Cell Lung Cancer · Lung Cancer (NSCLC) · Metastatic NSCLC - Non-Small Cell Lung Cancer · Metastatic Non-Squamous Non-Small Cell Lung Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 430 (planned)
- Started
- Aug 14, 2026
- Main results expected
- Oct 2029
- Fully finished
- Feb 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression free survival (PFS)
Measured over: Up to approximately 5 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07777822 · record last updated 2026-11-04 · checked 2026-11-09 15:47 UTC